DOSE RANGING EFFICACY, SAFETY, AND PHARMACOKINETIC STUDY OF RS25259

本研究的目的是：（1）确定剂量-反应关系 RS-25259单次静脉给药与剂量之间的关系 范围为0.3-30微克/千克。主要终点为以下患者的比例： 完全止吐反应（无呕吐或干呕）的患者 高度致吐化疗后24小时，化疗初治 癌症患者。 将每种剂量的疗效与 最低剂量的功效。 (2)评估单次给药的安全性 在剂量范围内静脉给药RS-25259 在这个患者群体中进行测试。 (3)评估药代动力学 在试验剂量范围内，RS-25259单次静脉给药 in this patient患者population人口.

The purposes of this study are: (1) To determine the dose-response relationship among single intravenous doses of RS-25259 over the dose range 0.3-30 ug/kg. The primary endpoint will be the proportion of patients with a complete antiemetic response (no vomiting or retching) for 24 hours after highly emetogenic chemotherapy, in chemotherapy-naive cancer patients. The efficacy of each dose will be compared with the efficacy of the lowest dose. (2) To assess the safety of single intravenous doses of RS-25259 administered through the range of doses tested in this patient population. (3) To assess the pharmacokinetics of single intravenous doses of RS-25259 through the range of doses tested in this patient population.